A cellular and spatial atlas of <i>TP53</i> -associated tissue remodeling in lung adenocarcinoma

William Zhao(Icahn School of Medicine at Mount Sinai), Benjamin Kepecs(Icahn School of Medicine at Mount Sinai), Navin R. Mahadevan(Brigham and Women's Hospital), Åsa Segerstolpe(Broad Institute), Jason L. Weirather, N. Besson(Center for Neuro-Oncology), Bruno Giotti(Icahn School of Medicine at Mount Sinai), Brian Y. Soong(Icahn School of Medicine at Mount Sinai), Chendi Li(Harvard University), Sébastien Vigneau(Center for Cancer Research), Michal Slyper(Broad Institute), Isaac Wakiro(Memorial Sloan Kettering Cancer Center), Judit Jané‐Valbuena(Broad Institute), Orr Ashenberg(Broad Institute), Asaf Rotem(Center for Cancer Research), Raphael Bueno(Men's Health Boston), Orit Rozenblatt–Rosen(Broad Institute), Kathleen L. Pfaff(Center for Neuro-Oncology), Scott J. Rodig(Brigham and Women's Hospital), Aaron N. Hata(Harvard University), Aviv Regev(Broad Institute), Bruce E. Johnson(Center for Cancer Research), Alexander M. Tsankov(Broad Institute)
bioRxiv (Cold Spring Harbor Laboratory)
June 29, 2023
Cited by 5Open Access
Full Text

Abstract

ABSTRACT TP53 is the most frequently mutated gene across many cancers and is associated with shorter survival in lung adenocarcinoma (LUAD). To define how TP53 mutations affect the LUAD tumor microenvironment (TME), we constructed a multi-omic cellular and spatial tumor atlas of 23 treatment-naïve human lung tumors. We found that TP53 -mutant ( TP53 mut ) malignant cells lose alveolar identity and upregulate highly proliferative and entropic gene expression programs consistently across resectable LUAD patient tumors, genetically engineered mouse models, and cell lines harboring a wide spectrum of TP53 mutations. We further identified a multicellular tumor niche composed of SPP1 + macrophages and collagen-expressing fibroblasts that coincides with hypoxic, pro-metastatic expression programs in TP53 mut tumors. Spatially correlated angiostatic and immune checkpoint interactions, including CD274 - PDCD1 and PVR - TIGIT , are also enriched in TP53 mut LUAD tumors, which may influence response to checkpoint blockade therapy. Our methodology can be further applied to investigate mutation-specific TME changes in other cancers.


Related Papers

No related papers found

Powered by citation graph analysis